Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

Journal of Clinical Oncology

Volumn 14, Issue 12, 1996, Pages 3085-3096

  Baker, S D ^a   Khor, S P ^a   Adjei, A A ^a   Doucette, M ^a   Spector, T ^a   Donehower, R C ^a   Grochow, L B ^a   Sartorius, S E ^a   Noe, D A ^a   Hohneker, J A ^a   Rowinsky, E K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; CREATININE; ENZYME INHIBITOR; FLUOROURACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 10544243363     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.12.3085     Document Type: Article

References (32)

1. Sotos GA, Grogan L, Allegra CJ: Preclinical and clinical aspects of bimodulation of 5-fluorouracil. Cancer Treat Rev 20:11-49, 1994
2. Kemeny N: Chemotherapy for colorectal carcinoma: One small step forward, one step backward. J Clin Oncol 13:1287-1290, 1995 (editorial)
3. de Takats PG, Kerr DJ, Poole CJ, et al: Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer 69:372-378, 1994
4. Hansen RM: 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. Cancer Invest 9:637-642, 1991
5. Diasio RB, Harris BE: Clinical Pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989
6. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253, 1994
7. Naguib FNM, El Kouni MH, Sha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5402-5412, 1985
8. Spector T, Harrington JA, Porter DJ: 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993
9. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993
10. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249, 1985
11. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyridinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51, 1988
12. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome. Cancer 68:499-501, 1991
13. Fleming RA, Milano GA, Gaspard MH, et al: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29A:740-744, 1993
14. Houyau P: Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 85:1602-1603, 1993
15. Harris BE, Song R, Soong S-J, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
16. Porter DJT, Chestnut WG, Merrill BM, et al: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267:5236-5242, 1992
17. Baccanari DP, Davis ST, Knick VC, et al: 776C85: Effects on the pharmacokinetics and antitumor activity of 5-fluorouracil. Proc Natl Acad Sci USA 90:11064-11068, 1993
18. Burris H, Schilsky R, Fields S, et al: Initial phase I trial of the dihydropyrimidine dehydrogenase inactivator 5-ethynyluracil (776C85) plus 5-fluorouracil. Proc Am Soc Clin Oncol 14:171, 1995 (abstr 368)
19. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994
20. Spector T, Cao S, Rustum YM, et al: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55:1239-1241, 1995
21. Fischel JL, Etienne MC, Spector T, et al: Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation. Clin Cancer Res 1:991-996, 1995
22. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
23. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982
24. Metzler CM: Extended least squares (ELS) for pharmacokinetic models. J Pharm Sci 76:565-571, 1987
25. Yamaoka K, Nakagaawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
26. Lalonde RL: Pharmacodynamics, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA, Applied Therapeutics, 1992, pp 4-1-4-33
27. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976.
28. Grem JL: Fluorinated pyrimidines, in Chabner CA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 180-224
29. Santini J, Milano G, Thyss A, et al: 5-Fluorouracil therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989
30. Wihlm J, Leveque D, Klein T: Pharmacodynamics of 5-fluorouracil combined with carboplatin in patients with head and neck cancer. Anticancer Res 14:2395-2396, 1994
31. Milano G, Etienne MC, Renee N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994
32. Wajima T, Mukhopadhyay P: Possible interactions between warfarin and 5-fluorouracil. Am J Hematol 40:238, 1992 (letter)